

The Selection and Use of Essential Medicines

Report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children)



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world.

To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaption. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The WHO *Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

To purchase WHO publications, please contact: WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int; order on line: <http://www.who.int/bookorders>).

The Selection and Use of Essential Medicines

Report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children)

This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization



**World Health
Organization**

The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children).

(WHO Technical Report Series, No. 1021)

ISBN 978-92-4-121030-0

ISSN 0512-3054

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Printed in Italy

Contents

Executive summary	vii
List of participants	xxxv
Declaration of interests for Expert Committee Members and Temporary Advisers	xxxvii
1. Introduction	1
2. Open session	2
3. Follow-up items and EML Working Groups	3
4. Summary of changes	13
5. Applications for the 21st Model List of Essential Medicines and the 7th Model List of Essential Medicines for Children	19
Section 6: ANTI-INFECTIVE MEDICINES	19
6.2 Antibacterials	19
Antibiotics for typhoid fever	19
Antibiotics for surgical prophylaxis	27
Antibiotics for oral and dental infections	39
Ceftazidime + avibactam – addition – EML	47
Ceftolozane + tazobactam – addition – EML	52
Delafloxacin – addition – EML	57
Eravacycline – addition – EML	61
Meropenem + vaborbactam – addition – EML	66
Omadacycline – addition – EML	70
Plazomicin – addition – EML	75
Antituberculosis medicines – new formulations for addition – EML and EMLc	79
Antituberculosis medicines – formulations for deletion – EML	84
Antituberculosis medicines – intravenous formulations for addition – EML and EMLc	87
Bedaquiline – addition – EMLc	92
Capreomycin and kanamycin – deletion – EML and EMLc	96
Delamanid – change age restriction – EMLc	99
Group C antibiotics for MDR-TB – new indication – EML and EMLc	102
Isoniazid – new formulation (oral liquid) – EMLc	109
6.4 Antiviral medicines	114
Antiretrovirals – formulations for deletion – EML and EMLc	114
Ritonavir – new formulation – EML and EMLc	118
Lopinavir + ritonavir – new formulation – EML and EMLc	123
Dolutegravir – addition – EMLc	127
Raltegravir – new formulation – EML and EMLc	133
Dolutegravir + lamivudine + tenofovir disoproxil fumarate – addition – EML	138
Glecaprevir + pibrentasvir – addition – EML	144
6.5 Antiprotozoal medicines	150
Sulfadoxine + pyrimethamine – new indication IPTi – EMLc	150
Sulfadoxine + pyrimethamine – new indication IPTp – EML	155

Amodiaquine with sulfadoxine + pyrimethamine – addition – EMLc	161
Fexinidazole – addition – EML and EMLc	166
6.6 Medicines for ectoparasitic infections	173
Ivermectin – new indication scabies – EML and EMLc	173
Section 7: ANTIMIGRAINE MEDICINES	179
7.1 For treatment of acute attack	179
Sumatriptan – addition – EML	179
Section 8: IMMUNOMODULATORS AND ANTINEOPLASTICS	188
8.1 Immunomodulators for non-malignant disease	188
Medicines for multiple sclerosis – addition – EML and EMLc	188
TNF-alfa inhibitors for chronic inflammatory diseases – addition – EML and EMLc	202
8.2 Antineoplastics and supportive medicines	214
Cancer medicines for children – addition/new indication – EMLc	214
Cancer medicines for children – text clarifications	227
Arsenic therapies – addition – EML and EMLc	232
Medicines for cervical cancer – new indication – EML	241
Pegaspargase – addition – EML and EMLc	251
Pertuzumab – addition – EML	257
Rituximab – new formulation – EML	271
Trastuzumab – new formulation – EML	276
Trastuzumab emtansine – addition – EML	281
Tyrosine-kinase inhibitors for non-small cell lung cancer – addition – EML	293
Medicines for multiple myeloma – addition – EML	302
Anti PD-1/PD-L1 Immune checkpoint inhibitors – addition – EML and EMLc	314
Medicines for prostate cancer – addition – EML	332
Section 10: MEDICINES AFFECTING THE BLOOD	339
10.2 Medicines affecting coagulation	339
Direct oral anticoagulants (DOACs) – dabigatran, rivaroxaban, apixaban, edoxaban – addition – EML	339
Section 12: CARDIOVASCULAR MEDICINES	356
12.3 Antihypertensive medicines	356
Fixed-dose combination antihypertensives – addition – EML	356
12.5 Antithrombotic medicines	367
Alteplase – addition – EML	367
Section 17: GASTROINTESTINAL MEDICINES	373
17.2 Antiemetic medicines	373
Aprepitant – addition – EML and EMLc	373
Ondansetron – square box – EML and EMLc	380
17.5 Medicines used in diarrhoea	383
Oral rehydration salts (ORS) and zinc (co-packaged) – new formulation – EMLc	383
Section 18: MEDICINES FOR ENDOCRINE DISORDERS	387
18.5 Insulin and other medicines used for diabetes	387
Long-acting insulin analogues (including biosimilars) – addition – EML	387
18.6 Medicines for hypoglycaemia	405
Diazoxide – addition – EMLc	405

18.7 Thyroid hormones and antithyroid medicines	411
Medicines for first-line treatment of primary hyperthyroidism – review – EML and EMLc	411
Section 22: MEDICINES FOR REPRODUCTIVE HEALTH AND PERINATAL CARE	417
22.3 Uterotonics	417
Carbetocin (heat-stable) – addition – EML	417
Mifepristone-misoprostol – change to listing – EML	422
Misoprostol – deletion of prevention of PPH indication – EML	429
Tranexamic acid – new indication – EML	434
Section 24: MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS	441
Methylphenidate – addition – EML and EMLc	441
24.2 Medicines used in mood disorders	450
Escitalopram – addition – EML	450
Fluoxetine – addition of square box – EML	450
Section 25: MEDICINES ACTING ON THE RESPIRATORY TRACT	457
25.1 Antiasthmatic and medicines for chronic obstructive pulmonary disease	457
Tiotropium – addition – EML	457
Section 27: VITAMINS AND MINERALS	463
Iodine – change to listing – EML and EMLc	463
Multiple micronutrient powders – addition – EMLc	465
Annex 1	471
WHO Model List of Essential Medicines (2019)	471
Annex 2	545
WHO Model List of Essential Medicines for Children (2019)	545
Annex 3	597
The Anatomical Therapeutic Chemical (ATC) Classification System	597
Annex 4	627
Alphabetical list of essential medicines (with ATC classification code numbers)	627

预览已结束，完整报告链接

<https://www.yunbaogao.cn/report/index/repo>